Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
Axsome is heading to regulators in the wake of a second successful depression study, and investors are predicting huge success. What could possibly go wrong?
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.